Corona Virus Covid 19

Big Daddy

Super User
Corruption is a slippery slope. One you take it, you can never recover. America is Capitalist but it also tries to maintain its values as best as it can. This is why Trump lost. It is not ok to lose morals. Most of the countries in the world are a mess because they have no morals. If America does this then Americans will have a problem and companies' CEO will be answering questions in front of Congress.
 

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
Check CoronaVaccination etc data in this link:

You can see for any age group or all. Second map in this link
 

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
Bharat Biotech Seeks Approval For Nasal Vaccine Trials In India: All You Need To Know
16,413 views
•Jan 8, 2021


152
9


India Today


4.71M subscribers

Coronavirus Vaccine News Updates: Bharat Biotech sends proposal to Drugs Controller General of India (DCGI) to seek approval for trials of its nasal vaccine against Covid-19 in India. Watch full bulletin.
 

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
Will Bharat Biotech's 'Nasal Vaccine' become game-changer for India?
53,536 views
•May 14, 2021


1K
61


ABP NEWS


29.3M subscribers

Will Bharat Biotech's 'Nasal Vaccine' become game-changer for India? Have a look at the video to know what is nasal vaccine, how it is used and what are its benefits. When can we get it? The vaccine company has already started trials for it
 

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
Plea in Supreme Court seeks COVID-19 vaccine trials’ data
Legal CorrespondentNEW DELHI , MAY 14, 2021 18:34 IST
UPDATED: MAY 14, 2021 18:35 IST

1621193757940.png

Lack of transparency raises concerns over efficacy and safety of two vaccines: petitioner
A petition has been filed in the Supreme Court to make public the segregated data of clinical trials of COVID-19 vaccines administered under the Emergency Use Authorisation granted by the Drugs Controller General of India (DCGI).

Former member of National Technical Advisory Group on Immunisation Dr. Jacob Puliyel, represented by advocate Prashant Bhushan, asked the court to direct the government, its bodies and the vaccine manufacturers – the Serum Institute of India and Bharat Biotech -to transparently reveal clinical trial and vaccination data, including the recording and reporting of adverse events.

Further, the petition urged the court to direct the government to not issue any “coercive mandates” for use of “these inadequately tested vaccines”.

Mr. Bhushan argued that courts should “reiterate that vaccine mandates are repugnant to the right of humans to autonomy and right to self-determine what may be injected into their bodies”.


“The respondents (Centre, its agencies like DCGI and ICMR and vaccine manufacturers) have maintained opacity about the clinical trial data of the two vaccines administered through emergency authorisation in India. Non-disclosure of this important data violates the basic ethics of clinical research that requires results of clinical research studies to be published and brought to the knowledge of the medical community, participants to the research and the general population,” the petition said.

Dr. Puliyel, also represented by advocate Cheryl d’Souza, said the lack of transparency raised concerns over the efficacy and safety of the two vaccines.

WHO statement
“The World Health Organisation (WHO) has released a strong statement advocating for public disclosure of all clinical trial results. According to the statement, when data is not released it means that doctors, patients and medical regulators cannot make informed decisions about which treatments are best,” the petition stated.

The petition said transparency in publishing clinical trial data by the Central Drugs Standard Controls Organisation (CDSCO) that granted final approval for the vaccines by various manufactures to enter the immunisation chain flowed from Section 4 of the Right to Information Act, 2005, which required the government to make “proactive disclosures of its records through the internet and other means of communications to the general public”.

The petition said the authorities should carefully monitor vaccine recipients and publicly record all adverse events.

“In other countries, this type of observation has helped identify the occurrence of blood clots and strokes in vaccine recipients. Many countries had stopped administering the vaccine till they evaluated this occurrence. Countries like Denmark have completely banned the use of the Astra zeneca vaccine (branded as Covishield in India),” it stated.

Adverse events
Mr. Bhushan argued that India, with its huge population and numbers vaccinated, should have reported these adverse events first.

“But due to poor follow-up, poor Adverse Events Following Immunisation (AEFI) evaluation and suppression of data, these events have not been put in the public domain - endangering many more to suffer the same fate,” the plea said.

Plea in Supreme Court seeks COVID-19 vaccine trials’ data
 

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
Explained: How does 2-DG, DRDO’s new oral drug for Covid-19, work?

DRDO 2-DG Medicine: The Drugs Controller General of India (DCGI) had cleared the formulation on May 1 for emergency use as an adjunct therapy in moderate to severe Covid-19 patients.


By: Explained Desk | New Delhi |
Updated: May 18, 2021 12:22:54 pm


drdo 2dg medicine, drdo 2dg medicine uses, drdo 2dg medicine price, drdo 2dg medicine price in india, drdo 2dg medicine uses, drdo 2dg medicine efficacy, drdo 2dg medicine availability, drdo 2dg medicine dosage



DCGI approves anti-COVID drug developed by DRDO for emergency use. (PTI Photo)

Defence Minister Rajnath Singh and Health Minister Dr Harsh Vardhan on Monday (May 17) released the first batch of the indigenously developed anti-Covid-19 drug, 2-deoxy-D-glucose or ‘2-DG’.
The national drug regulator, Drugs Controller General of India (DCGI), had cleared the formulation on May 1 for emergency use as an adjunct therapy in moderate to severe Covid-19 patients.


The formulation
2-DG has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), New Delhi, a lab of the Defence Research and Development Organisation (DRDO), in collaboration with Hyderabad-based pharma company Dr Reddy’s Laboratories (DRL), the Ministry of Defence had said in a release earlier this month.


How it works
According to the government release, clinical trial data show that the molecule helps in faster recovery of patients hospitalised with Covid-19, and reduces their dependence on supplemental oxygen.
The drug accumulates in virus-infected cells, and prevents the growth of the virus by stopping viral synthesis and energy production. Its selective accumulation in virally-infected cells makes this drug unique, the release said.
“The drug will be of immense benefit to the people suffering from Covid-19,” it said.


Clinical trials
During the first wave of the pandemic in April 2020, laboratory experiments carried out by scientists of INMAS-DRDO in collaboration with the Centre for Cellular and Molecular Biology (CCMB), Hyderabad, found that this molecule works effectively against SARS-CoV-2, the coronavirus that causes the Covid-19 disease, and inhibits viral growth.
In May 2020, the Central Drugs Standard Control Organization (CDSCO) of the DCGI permitted phase 2 clinical trials of 2-DG in Covid-19 patients.
DRDO and its industry partner, DRL, conducted phase 2 trials on 110 patients between May and October last year, the government said. Phase 2a was conducted in six hospitals, and phase 2b (dose ranging) was conducted at 11 hospitals across the country.
On the basis of successful phase 2 clinical trials data, DCGI permitted phase 3 clinical trials in November 2020. Between December 2020 and March 2021, late stage trials were carried out on 220 patients admitted to 27 Covid hospitals in Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu, the government said.


Trial data
The phase 2 clinical trials were carried out to test the safety and efficacy of the drug in Covid-19 patients. 2-DG was found to be safe in Covid-19 patients, and showed significant improvement in their recovery, the government release said.
In efficacy trends, “the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints”, the release said.
“A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving normalisation of specific vital signs parameters when compared to SoC.”
Data from the phase 3 clinical trial showed that in the 2-DG arm, a “significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by Day 3 in comparison to SoC, indicating an early relief from oxygen therapy/dependence”, the government said.
A similar trend was observed in patients aged more than 65 years.

Advantages
According to the government, 2-DG being a generic molecule and an analogue of glucose, it can be easily produced and made available in large quantities.

The drug is available in powder form in a sachet, and can be taken orally after dissolving in water.


Explained: How does 2-DG, DRDO’s new oral drug for Covid-19, work?
 

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
DRDO's Anti-COVID Drug 2DG Launched | 2-DG Covid-19 | 2DG Drug Covid | CNN News18
9,161 views
•May 17, 2021


100
1


CNN-News18


1.79M subscribers

Defence Minister Rajnath Singh and Union Health Minister Dr Harsh Vardhan released the first batch of Anti-COVID drug 2DG developed by DRDO.

We will not be at ease and will not be tired but will keep fighting and will win against #COVID19. Under the leadership of PM, the issue of oxygen production has been resolved with collective effort. Now medicine issue is also not there much: Union Defence Minister Rajnath Singh.

The first batch of anti-COVID drug 2-DG, developed by the DRDO, was released today by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan. The Drugs Controller General of India (DCGI) has approved the oral drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients, the defence ministry said earlier this month. The officials said the first batch of the drug will be released by the two ministers at an event at the headquarters of the Defence Research and Development Organisation (DRDO) here. The ministry, on May 8, said the clinical trials of the drug, 2-deoxy-D-glucose (2-DG), showed that it helps in a faster recovery of hospitalised patients and reduces supplemental oxygen dependence.

The approval of the drug has come at a time when India is grappling with a record-breaking wave of the coronavirus pandemic that has stretched the country’s healthcare infrastructure to its limit. “In the ongoing second COVID-19 wave, a large number of patients are facing severe oxygen dependency and need hospitalisation. The drug is expected to save precious lives due to the mechanism of its operation in the infected cells. This also reduces the hospital stay of COVID-19 patients,” the ministry had said. The anti-COVID therapeutic application of the drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of the DRDO, in collaboration with Dr Reddy’s Laboratories (DRL) in Hyderabad. The drug comes in a powder form in a sachet and is taken orally by dissolving it in water, the ministry said. In efficacy trends, it said, patients treated with 2-DG showed a faster symptomatic cure than the standard of care (SoC) on various endpoints.

DRDO
2dgdrug
CNNNews18
 
Top